PYC Therapeutics Statistics
Total Valuation
PYCXF has a market cap or net worth of 704.50 million. The enterprise value is 596.60 million.
| Market Cap | 704.50M |
| Enterprise Value | 596.60M |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 583.26M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +27.16% |
| Shares Change (QoQ) | +14.51% |
| Owned by Insiders (%) | 38.33% |
| Owned by Institutions (%) | 9.56% |
| Float | 313.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 45.74 |
| PB Ratio | 6.32 |
| P/TBV Ratio | 6.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -18.09 |
| EV / Sales | 35.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.32 |
Financial Position
The company has a current ratio of 14.41, with a Debt / Equity ratio of 0.01.
| Current Ratio | 14.41 |
| Quick Ratio | 14.38 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -861.86 |
Financial Efficiency
Return on equity (ROE) is -40.64% and return on invested capital (ROIC) is -26.48%.
| Return on Equity (ROE) | -40.64% |
| Return on Assets (ROA) | -24.42% |
| Return on Invested Capital (ROIC) | -26.48% |
| Return on Capital Employed (ROCE) | -31.37% |
| Weighted Average Cost of Capital (WACC) | 9.12% |
| Revenue Per Employee | 3.08M |
| Profits Per Employee | -6.60M |
| Employee Count | 5 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.89 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 75.32 |
| Average Volume (20 Days) | 11,094 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PYCXF had revenue of 15.40 million and -32.98 million in losses. Loss per share was -0.07.
| Revenue | 15.40M |
| Gross Profit | 15.40M |
| Operating Income | -35.16M |
| Pretax Income | -33.44M |
| Net Income | -32.98M |
| EBITDA | -34.67M |
| EBIT | -35.16M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 100.34 million in cash and 671,174 in debt, with a net cash position of 99.67 million.
| Cash & Cash Equivalents | 100.34M |
| Total Debt | 671,174 |
| Net Cash | 99.67M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 111.46M |
| Book Value Per Share | 0.19 |
| Working Capital | 108.31M |
Cash Flow
In the last 12 months, operating cash flow was -33.80 million and capital expenditures -639,479, giving a free cash flow of -34.44 million.
| Operating Cash Flow | -33.80M |
| Capital Expenditures | -639,479 |
| Free Cash Flow | -34.44M |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -228.26% and -214.11%.
| Gross Margin | 100.00% |
| Operating Margin | -228.26% |
| Pretax Margin | -217.13% |
| Profit Margin | -214.11% |
| EBITDA Margin | -225.06% |
| EBIT Margin | -228.26% |
| FCF Margin | n/a |
Dividends & Yields
PYCXF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.16% |
| Shareholder Yield | -27.16% |
| Earnings Yield | -4.68% |
| FCF Yield | -4.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PYCXF has an Altman Z-Score of 28.91 and a Piotroski F-Score of 1.
| Altman Z-Score | 28.91 |
| Piotroski F-Score | 1 |